Cardiovascular Disease News and Research RSS Feed - Cardiovascular Disease News and Research

According to the Centers for Disease Control and Prevention, about 700,000 people die annually of cardiovascular disease. Cardiovascular disease involves the heart and vessels and is the number one killer in the U.S. accounting for nearly 30-percent of all deaths. Cardiovascular disease has a number of forms but the most common are myocardial infarction and angina pectoris which affect the heart itself. There are well known environmental risk factors associated with cardiovascular disease such as smoking, diet, inactivity and increased alcohol use. Heredity also plays a factor in cardiovascular disease since other risk factors like high blood pressure and high LDL cholesterol tend to run in families. Cardiovascular disease can be reduced by controlling environmental factors and understanding the genetic factors that put people at greater risk for heart disease.
CT angiography provides accurate assessment of arterial plaque in diabetic patients

CT angiography provides accurate assessment of arterial plaque in diabetic patients

Imaging of the coronary arteries with computed tomography (CT) angiography provides an accurate assessment of arterial plaque and could have a dramatic impact on the management of diabetic patients who face a high risk of heart attacks and other cardiovascular events, according to a new multicenter study published online in the journal Radiology. [More]
Synageva announces publication of LAL Deficiency review in Atherosclerosis

Synageva announces publication of LAL Deficiency review in Atherosclerosis

Synageva BioPharma Corp., a biopharmaceutical company developing therapeutic products for rare diseases, today announced the publication of an overview of lysosomal acid lipase deficiency (LAL Deficiency) in the online version and an upcoming print edition of Atherosclerosis, the official journal of the European Atherosclerosis Society. [More]
Highly advanced imaging method helps to monitor rapid changes in glutathione redox potentials in live cells

Highly advanced imaging method helps to monitor rapid changes in glutathione redox potentials in live cells

In the April issue of Experimental Biology and Medicine a multidisciplinary research team led by Drs. Rex Gaskins and Paul Kenis in the Institute of Genomic Biology (IGB) on the campus of the University of Illinois Urbana-Champaign describe their recent work on subcellular redox homeostasis. [More]
Genmab/GSK receive FDA sBLA approval for Arzerra in combination with chlorambucil for treatment of CLL

Genmab/GSK receive FDA sBLA approval for Arzerra in combination with chlorambucil for treatment of CLL

GlaxoSmithKline plc and Genmab A/S announced today that the U.S. Food and Drug Administration (FDA) has approved a Supplemental Biologic License Application (sBLA) for the use of Arzerra® (ofatumumab), a CD20-directed cytolytic monoclonal antibody, in combination with chlorambucil for the treatment of previously untreated patients with chronic lymphocytic leukaemia (CLL) for whom fludarabine-based therapy is considered inappropriate. [More]

Scientist receives $1.8M defense grant from Kessler Foundation for spinal cord injury research

Kessler Foundation has been named awardee of a three-year grant for $1.8 million from the Department of Defense Spinal Cord Injury Research Program. Gail Forrest, PT, PhD, is principal investigator for the randomized, double-blinded, controlled, multi-site clinical trial, which will test strategies to improve bone and muscle strength after spinal cord injury. Dr. Forrest is assistant director of Human Performance & Engineering Research at Kessler Foundation. [More]

ARCA biopharma announces genetic screening of first patient in GENETIC-AF Phase 2B/3 clinical trial

ARCA biopharma, Inc., a biopharmaceutical company developing genetically targeted therapies for cardiovascular diseases, today announced that the first patient has been genetically screened in GENETIC-AF, its Phase 2B/3 adaptive design clinical trial. [More]

SCRA Technology Ventures announces sale of Selah Genomics to EKF Diagnostics

SCRA Technology Ventures today announced that portfolio company Selah Genomics was sold to EKF Diagnostics, a publically-traded UK-based diagnostics firm. Selah, a provider of advanced molecular and genomic diagnostic services, completed the deal today, making it the largest of nine exits out of the SC Launch program since 2006. [More]
Combination therapy could help prevent cardiovascular disease

Combination therapy could help prevent cardiovascular disease

Taking one pill instead of three could be a powerful ally to prevent cardiovascular disease, according to a new Cochrane systematic review of the latest research on polypills from a team of scientists at the London School of Hygiene & Tropical Medicine, Warwick Medical School and Northwestern Medicine. [More]

NICE recommends FIRMAGON for treating advanced hormone-dependent prostate cancer in adults with spinal metastases

The National Institute for Health and Care Excellence (NICE) today issued its Final Appraisal Determination (FAD) recommending FIRMAGON (degarelix) as an option for treating advanced hormone-dependent prostate cancer, only in adults with spinal metastases who present with signs or symptoms of spinal cord compression. [More]

Dental researchers find new way to study how mouth's natural defenses ward off infection, inflammation

Case Western Reserve University dental researchers have found a less invasive way to extract single rare immune cells from the mouth to study how the mouth's natural defenses ward off infection and inflammation. [More]
Researchers reveal why Peel has one of highest rates of diabetes in Ontario

Researchers reveal why Peel has one of highest rates of diabetes in Ontario

According to researchers at St. Michael's Hospital, there are two significant reasons why Peel has one of the highest rates of diabetes in Ontario: neighbourhood design that discourages walking and a population with many residents whose ethnic backgrounds predispose them to diabetes. [More]
Two Penn researchers selected as recipients of prestigious Clinical Research Achievement Award

Two Penn researchers selected as recipients of prestigious Clinical Research Achievement Award

Two researchers from the Perelman School of Medicine at the University of Pennsylvania and the Penn Cardiovascular Institute are among the 2014 recipients of the prestigious Clinical Research Achievement Award for their work in cardiovascular science. [More]
Studies provide evidence to clarify role of NAFLD as independent risk factor for development of CVD

Studies provide evidence to clarify role of NAFLD as independent risk factor for development of CVD

Two new studies presented today at the International Liver CongressTM 2014 have provided more evidence to clarify the role of non-alcoholic fatty liver disease (NAFLD) as an independent risk factor for the development of cardiovascular disease (CVD). [More]

Study describes how overeating causes brown fat cells to "whiten"

Boston University researchers have learned new information about the consequences of overeating high-calorie foods. Not only does this lead to an increase in white fat cell production, the type prominent in obesity, but it also leads to the dysfunction of brown fat cells, the unique type of fat that generates heat and burns energy. [More]

Millennium Medical Devices inks another network selling agreement

Millennium HealthCare Inc. today announced that its subsidiary, Millennium Medical Devices LLC, has signed yet another network selling agreement. This agreement was signed with a US based healthcare organization for the use of Millennium's medical devices in 400 of the organization's locations. This agreement includes an average monthly minimum use of 350 units per device, per location. [More]
Pradaxa receives FDA approval for treatment and reduction of risk of recurrence of DVT and PE

Pradaxa receives FDA approval for treatment and reduction of risk of recurrence of DVT and PE

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Pradaxa® (dabigatran etexilate mesylate) for the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have been treated with a parenteral anticoagulant for five to 10 days, and to reduce the risk of recurrent DVT and PE in patients who have been previously treated. DVT and PE are collectively referred to as venous thromboembolism (VTE). [More]

Children exposed to 'green exercise' more likely to experience health-enhancing effects after activity

​Children who are exposed to scenes of nature while exercising are more likely to experience health-enhancing effects after activity, according to a Coventry University study published this week in the International Journal of Environmental Research and Public Health. [More]
Research: Chronic sleep deprivation linked to heart failure

Research: Chronic sleep deprivation linked to heart failure

Poor sleep doubles hospitalisations in heart failure, according to new research in nearly 500 patients presented today at EuroHeartCare 2014. [More]

Nurses guide patients into trance during procedure

Visualising a safe place reduces operative pain, according to research presented today at EuroHeartCare 2014. Nurses guided patients into a trance and found it helped patients cope with pain and anxiety during ablation of atrial fibrillation (AF). [More]
Study: Moderate to severe depression increases risk of heart failure by 40%

Study: Moderate to severe depression increases risk of heart failure by 40%

Moderate to severe depression increases the risk of heart failure by 40%, a study of nearly 63 000 Norwegians has shown. The findings were presented for the first time today at EuroHeartCare 2014. [More]